Pharmacological treatment options for T2D have expanded in recent years and now include insulin, metformin, glucagon-like peptide-1 (GLP-1) agonists, and sodium-glucose cotransporter 2 (SGLT2) inhibitors. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.